Arcus Biosciences, Inc.
Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Abstract:

Compounds of Formula I that inhibit at least one of the A.sub.2A and A.sub.2B adenosine receptors, and compositions containing compounds of Formula I and methods for synthesizing compounds of Formula I, are described herein. ##STR00001## Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A.sub.2A receptor and/or the adenosine A.sub.2B receptor.